Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome.
about
Ectopic lymphoid neogenesis in rheumatic autoimmune diseases.Preclinical validation of salivary biomarkers for primary Sjögren's syndromeRituximab in primary Sjögren's syndrome: a ten-year journey.Genetics and genomics of Sjögren's syndrome: research provides clues to pathogenesis and novel therapies.Chitinases in the salivary glands and circulation of patients with Sjögren's syndrome: macrophage harbingers of disease severity.Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome.Autoimmunity at the ocular surface: pathogenesis and regulation.Systems analysis of primary Sjögren's syndrome pathogenesis in salivary glands identifies shared pathways in human and a mouse model.Quantitative assessment of oral mucosa and labial minor salivary glands in patients with Sjögren's syndrome using swept source OCT.Immunomodulatory drugs: oral and systemic adverse effects.Emerging biotherapies for Sjögren's syndrome.What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?Biological therapies in primary Sjögren's syndrome.Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?Biologics in oral medicine: Sjogren syndrome.Sjögren's syndrome in older patients: aetiology, diagnosis and management.B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies.The value of animal models to study immunopathology of primary human Sjögren's syndrome symptoms.B-cell hyperactivity in primary Sjögren's syndrome.Immune-mediated diseases: what can be found in the oral cavity?Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare.Functional salivary gland regeneration as the next generation of organ replacement regenerative therapy.Safety of treatments for primary Sjögren's syndrome.Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.Present and future of biologic drugs in primary Sjögren's syndrome.Rituximab efficiently depletes B cells in lung tumors and normal lung tissue.Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.Topical and systemic medications for the treatment of primary Sjögren's syndrome.Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren’s syndrome: a pilot study.Management of primary Sjögren's syndrome: recent developments and new classification criteria.TLR-7 and -9 Stimulation of Peripheral Blood B Cells Indicate Altered TLR Signalling in Primary Sjögren's Syndrome Patients by Increased Secretion of Cytokines.Transient depletion of CD4+ CD25+ regulatory T cells results in multiple autoimmune diseases in wild-type and B-cell-deficient NOD mice.Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome.Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug?Sjögren syndrome
P2860
Q30235935-D5B5A343-AA93-4C34-BD76-60752833CE8BQ34370333-88C6BE44-6451-4703-A978-9B6F908F18FAQ34432465-34FD72B4-07AA-47D0-9084-D5126FB18FC8Q34984739-A5441EA6-D018-4F65-A806-FAAA684933EBQ35242525-A5885FC1-B35F-4252-AA8A-B48FCCE29EAEQ36214855-6AB95E89-E9B3-49B9-892E-B6A642E926C8Q36625074-BED29031-82EA-4136-81DB-4B97F6D5AD92Q36907609-B894FF20-7FCF-4827-997E-B637631646DEQ37476885-73A65531-B43D-4885-8BF1-6CA7621DF18BQ37539743-2ECEC6EA-FF63-4482-8CAC-6FCD5350175FQ37729176-65B9A558-F1CD-4D1D-990B-184402AC54F4Q37849356-8248673D-5075-463A-93A2-80D7B48EB8AFQ37860347-85129627-BF54-4863-820C-6F7936F93E78Q37912214-3418B971-88F0-461B-8E6C-550C3F258D2EQ38002156-ECB5E35A-97FF-4C63-A150-EB3138FAAB1AQ38076070-96D5296E-00EC-4827-B1FD-620DECA1F393Q38097170-DA2A1967-7F14-4099-B5BE-14D778592AF5Q38186111-960AEC40-9114-4D14-A67C-E578006971D7Q38190590-9F22CA5E-1E98-4D49-8BFC-347AF3338438Q38290659-D8F700DA-8C96-4892-999E-2E174646F10BQ38538490-BC831E53-B9DF-4562-A4F2-B91E57B20A27Q38547269-B96DC88C-EED4-475D-937F-381AD9C0274DQ38711144-9215A4F6-DCFE-4C6A-9C0C-184BD170C692Q38795404-A3354972-DB25-4388-9BDF-D3C502A9827DQ38822415-47166837-23A7-41CE-A256-B4AB1811F595Q39680704-8FDB1EAD-6F82-477C-8C91-6E74F908C763Q40117123-50562E3A-86DF-4BA0-B1D2-B444F85E5618Q44498935-B6635383-9D34-45F2-9857-B1E4B8B40618Q44697565-75C660D7-72D8-4B95-A627-DBC68EF61CAEQ47700923-5B118E6A-AE24-4688-B3C5-22CCB66C4770Q50711764-4270B7C0-B0B5-4641-BD80-A7D4853A88DCQ51282774-B0DB9FB8-3384-4472-86C3-F2A650AF69DEQ53606687-3B014EBF-46C0-46FE-A0DA-1C7E11A023DAQ54384919-8BD33D15-9F67-4029-8A19-F94691515330Q55970262-790DA99A-9BBE-4F36-A35B-FDCFC1587231
P2860
Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Clinical and histologic eviden ...... eatment in Sjögren's syndrome.
@en
Clinical and histologic eviden ...... eatment in Sjögren's syndrome.
@nl
type
label
Clinical and histologic eviden ...... eatment in Sjögren's syndrome.
@en
Clinical and histologic eviden ...... eatment in Sjögren's syndrome.
@nl
prefLabel
Clinical and histologic eviden ...... eatment in Sjögren's syndrome.
@en
Clinical and histologic eviden ...... eatment in Sjögren's syndrome.
@nl
P2093
P2860
P356
P1476
Clinical and histologic eviden ...... eatment in Sjögren's syndrome.
@en
P2093
C G M Kallenberg
F K L Spijkervet
J E van der Wal
J M Meijer
P2860
P304
P356
10.1002/ART.24903
P577
2009-11-01T00:00:00Z